Retinal imaging company Optos celebrated installing more than 25,000 devices worldwide with the technology being studied across 2,500 clinical and peer reviewed studies, spanning 235 disease states.
‘This remarkable double milestone reflects the unwavering commitment that Optos has had to innovation and excellence in providing the best, clinically relevant technology available, since our inception,’ said Optos chief executive officer Robert Kennedy.
‘The ongoing growth and recognition of the robust body of clinical research efforts underscores the dedication of our team to continue improving patient outcomes and driving development in ophthalmic care.’
Optos, the only provider of single-capture ultra-widefield retinal imaging, showcased three of its devices at 100% Optical at London’s Excel centre on February 24-26.
All device platforms featured nine imaging modalities, including Optomap colour rgb, natural colour imaging modality and blue fundus autofluorescence, to diagnose, document, manage and treat ocular pathology.